FDA Oncology Announcements

IL-3 fused immunotoxin × Clear all

2 Announcements

FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Drug: ELZONRIS (tagraxofusp-erzs) · IL-3 fused immunotoxin
Condition: Myeloid

FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Drug: ELZONRIS (tagraxofusp-erzs) · IL-3 fused immunotoxin
Condition: Myeloid